$16.49
-0.93[-5.34%]
At close: May 17
$16.49
0[0.00%]
After Hours: 4:09PM EDT
TG Therapeutics
(NASDAQ:TGTX)Latest News for TG Therapeutics Stock (NASDAQ:TGTX)
TG Therapeutics Stock (NASDAQ: TGTX)
Categories: All
Tuesday, May 14, 2024
Thursday, May 02, 2024
Wednesday, May 01, 2024
- Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - May 1, 2024, 1:01PM
- Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - May 1, 2024, 10:27AM
- Watching TG Therapeutics; Hearing M&A Blog Says Strong Sales Forecast For Multiple Sclerosis Drug That May Draw SuitorsBenzinga Newsdesk - May 1, 2024, 10:03AM
- Market-Moving News for May 1 stBenzinga Newsdesk - May 1, 2024, 8:44AM
- Market-Moving News for May 1stBenzinga Newsdesk - May 1, 2024, 8:41AM
- TG Therapeutics shares are trading higher following a Q1 revenue beat and increased 2024 Briumvi US net product revenue outlook.Benzinga Newsdesk - May 1, 2024, 7:17AM
- TG Therapeutics Updates 2024 Briumvi U.S. Net Product Revenue Target To Approximately $270M-$290M Versus Prior Guidance Of $220M-$260MBenzinga Newsdesk - May 1, 2024, 7:10AM
- TG Therapeutics Targets Q2 2024 Briumvi U.S. Net Product Revenue Of Approximately $65MBenzinga Newsdesk - May 1, 2024, 7:09AM
- TG Therapeutics Q1 2024 GAAP EPS $(0.07) Misses $(0.04) Estimate, Sales $63.474M Beat $54.579M EstimateBenzinga Newsdesk - May 1, 2024, 7:02AM
Thursday, April 18, 2024
- HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price TargetBenzinga Newsdesk - Apr 18, 2024, 1:59PM
- JP Morgan Reiterates Overweight on TG Therapeutics, Maintains $25 Price TargetBenzinga Newsdesk - Apr 18, 2024, 1:30PM
- Ladenburg Thalmann Reiterates Buy on TG Therapeutics, Maintains $39 Price TargetBenzinga Newsdesk - Apr 18, 2024, 1:27PM
- TG Therapeutics Receives National Contract With The Department Of Veterans Affairs For Briumvi (Ublituximab) To Be The Preferred Agent Listed On VA National Formulary For Anti-CD20 Antibody Indications For Relapsing Forms Of Multiple SclerosisBenzinga Newsdesk - Apr 18, 2024, 7:44AM
- TG Therapeutics Announced Two Additional Data Presentations From ULTIMATE I And II Phase 3 Trials Evaluating Briumvi (Ublituximab) For Relapsing Forms Of Multiple Sclerosis At The 2024 American Academy Of Neurology Annual MeetingBenzinga Newsdesk - Apr 18, 2024, 7:40AM
Wednesday, April 17, 2024
Wednesday, March 13, 2024
Friday, March 08, 2024
Friday, March 01, 2024
- HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price TargetBenzinga Newsdesk - Mar 1, 2024, 2:22PM
- TG Therapeutics Announced Data Presentation From ULTIMATE I & II Phase 3 Trials And ENHANCE Phase 3b Trial Evaluating Briumvi For Relapsing Forms Of Multiple Sclerosis, At Americas Committee For Treatment And Research In Multiple Sclerosis Annual ForumBenzinga Newsdesk - Mar 1, 2024, 7:35AM
Thursday, February 29, 2024
Wednesday, February 28, 2024
- Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Feb 28, 2024, 2:02PM
- Why Is Multiple Sclerosis-Focused TG Therapeutics Stock Trading Higher Today?Vandana Singh - Feb 28, 2024, 1:20PM
- HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price TargetBenzinga Newsdesk - Feb 28, 2024, 12:38PM
- Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On WednesdayAvi Kapoor - Feb 28, 2024, 11:37AM
- TG Therapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.Benzinga Newsdesk - Feb 28, 2024, 9:01AM
- TG Therapeutics Q4 2023 Adj EPS $(0.09) Beats $(0.10) Estimate, Sales $43.97M Beat $40.06M EstimateBenzinga Newsdesk - Feb 28, 2024, 7:04AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
- TG Therapeutic shares are trading higher. The company announced the issuance of additional patents for BRIUMVI.Benzinga Newsdesk - Feb 27, 2024, 3:43PM
- Earnings Preview For TG TherapeuticsBenzinga Insights - Feb 27, 2024, 11:01AM
- TG Therapeutics Announced The Issuance Of Three US Additional Patents For Briumvi For Relapsing Forms Of Multiple Sclerosis That Can Be Administered In One-hour Infusion Following The Starting DoseBenzinga Newsdesk - Feb 27, 2024, 7:34AM
Monday, February 26, 2024
Friday, February 16, 2024
Monday, February 05, 2024
Friday, January 19, 2024
Thursday, January 11, 2024
Wednesday, January 10, 2024
- Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionAvi Kapoor - Jan 10, 2024, 1:06PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Jan 10, 2024, 12:31PM
- Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On WednesdayAvi Kapoor - Jan 10, 2024, 10:27AM
- Why Is Multiple Sclerosis Focused TG Therapeutics Stock Trading Higher Today?Lekha Gupta - Jan 10, 2024, 8:48AM
- Market-Moving News for January 10thBenzinga Newsdesk - Jan 10, 2024, 8:44AM
- Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 10, 2024, 8:02AM
- TG Therapeutics shares are trading higher after the company reported preliminary BRIUMVI US net product sales for Q4 and FY23.Benzinga Newsdesk - Jan 10, 2024, 7:41AM
- TG Therapeutics Expects Q1 BRIUMVI U.S. Net Product Revenue Of $41M - $46M; FY24 Revenue Of $220M - $260MBenzinga Newsdesk - Jan 10, 2024, 7:07AM